Strategic partnerships Active pursuit of licensing and development partnerships to advance Phase 3 trials for topical pravibismane and explore new indications suggests significant BD opportunities with pharma companies seeking late-stage assets or niche infection/orthopedic programs.

Orphan and Fast Track FDA QIDP, Fast Track, and Orphan Drug designations for pravibismane enhance attractiveness to potential partners by expediting development timelines and market access in rare and serious infections, reducing risk for collaborators.

Diverse indications Multiple formulations and routes (topical, local/surgical, inhaled) across diabetic foot infections, orthopedic infections, and NTM lung diseases indicate broad market expansion potential and tailored co-development deals with specialty franchises.

Public funding leverage Substantial non-dilutive funding from DoD, NIH, CARB-X, and CF Foundation totaling over 22 million demonstrates validated unmet need and program credibility, which can de-risk partnerships and attract strategic investors.

Regional focus Based in Bozeman, Montana with early-stage global partnerships, there is an opportunity to align with regional biopharma hubs, contract research organizations, and government grant ecosystems to accelerate clinical milestones and joint ventures.